This study demonstrates that the combination of nAchR antagonists with stress kinase inhibitors could significantly block xenograft growth in the presence of HFD plus nicotine, suggesting this combination therapy could potentially be used to treat obese breast cancer patients who smoke or use nicotine replacement therapy. Here, CHRNA4 is linked to breast carcinoma.